Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
NCT03860961 · View on ClinicalTrials.gov ↗
Study Summary
This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy. There is a need for coordinated care between the cancer care team with the primary care team. This is especially important for prostate cancer survivors who need routine cancer care follow-up with their radiation oncologist and also coordinated routine follow-up with their primary care provider (PCP). This is important because androgen deprivation therapy increases a patient's risk for developing diabetes, hypercholesterolemia, and cardiovascular events. Increasing the dose of survivorship may improve care and outcomes of cancer survivors than standard practices.
Conditions Studied
Interventions
- OTHER Treatment Plan
- OTHER Survivorship Care Plan
Study Locations (20)
California
- Kaiser Permanente Dublin — Dublin
- Kaiser Permanente Oakland-Broadway — Oakland
- Kaiser Permanente-Rancho Cordova Cancer Center — Rancho Cordova
- Rohnert Park Cancer Center — Rohnert Park
- The Permanente Medical Group-Roseville Radiation Oncology — Roseville
- Kaiser Permanente Medical Center - Santa Clara — Santa Clara
- Kaiser Permanente Cancer Treatment Center — South San Francisco
Idaho
- Saint Luke's Cancer Institute - Boise — Boise
- Saint Luke's Cancer Institute - Fruitland — Fruitland
- Saint Luke's Cancer Institute - Meridian — Meridian
- Saint Luke's Cancer Institute - Nampa — Nampa
- Saint Luke's Cancer Institute - Twin Falls — Twin Falls
Delaware
- Helen F Graham Cancer Center — Newark
- Christiana Care Health System-Christiana Hospital — Newark
- Beebe Health Campus — Rehoboth Beach
Illinois
- John H Stroger Jr Hospital of Cook County — Chicago
- Carle at The Riverfront — Danville
Arizona
- Kingman Regional Medical Center — Kingman
District of Columbia
- MedStar Georgetown University Hospital — Washington D.C.
Georgia
- Augusta University Medical Center — Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2019-07-26 |
| Est. Completion | 2025-09-04 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03860961
The ClinicalTrials.gov registry entry for NCT03860961 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 162 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions — of which Treatment Plan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03860961 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Idaho, Delaware. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03860961 about?
NCT03860961 is a clinical study titled "Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy". This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy. There is a need for coordinated care between the cancer care team with the primary care team. This is es...
What is the current status of trial NCT03860961?
This trial is currently completed. It is a NA study. The enrollment target is 550 participants. The study started on 2019-07-26. Estimated completion is 2025-09-04.
What conditions does trial NCT03860961 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03860961?
The interventions under investigation include: Treatment Plan (OTHER), Survivorship Care Plan (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03860961?
This trial is sponsored by NRG Oncology, which has 162 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03860961 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.